Abstract:BackgroundThe CXCR3 receptor and its three interferon-inducible ligands (CXCL9, CXCL10 and CXCL11) have been implicated as playing a central role in directing a Th1 inflammatory response. Recent studies strongly support that the CXCR3 receptor is a very attractive therapeutic target for treating autoimmune diseases, such as rheumatoid arthritis, multiple sclerosis and psoriasis, and to prevent transplant rejection. We describe here the in vitro and in vivo pharmacological characterizations of a novel and potent small molecule CXCR3 antagonist, SCH 546738.ResultsIn this study, we evaluated in vitro pharmacological properties of SCH 546738 by radioligand receptor binding and human activated T cell chemotaxis assays. In vivo efficacy of SCH 546738 was determined by mouse collagen-induced arthritis, rat and mouse experimental autoimmune encephalomyelitis, and rat cardiac transplantation models. We show that SCH 546738 binds to human CXCR3 with a high affinity of 0.4 nM. In addition, SCH 546738 displaces radiolabeled CXCL10 and CXCL11 from human CXCR3 with IC50 ranging from 0.8 to 2.2 nM in a non-competitive manner. SCH 546738 potently and specifically inhibits CXCR3-mediated chemotaxis in human activated T cells with IC90 about 10 nM. SCH 546738 attenuates the disease development in mouse collagen-induced arthritis model. SCH 546738 also significantly reduces disease severity in rat and mouse experimental autoimmune encephalomyelitis models. Furthermore, SCH 546738 alone achieves dose-dependent prolongation of rat cardiac allograft survival. Most significantly, SCH 546738 in combination with CsA supports permanent engraftment.ConclusionsSCH 546738 is a novel, potent and non-competitive small molecule CXCR3 antagonist. It is efficacious in multiple preclinical disease models. These results demonstrate that therapy with CXCR3 antagonists may serve as a new strategy for treatment of autoimmune diseases, including rheumatoid arthritis and multiple sclerosis, and to prevent transplant rejection.

Small Molecule Inhibits Activity of Scavenger Receptor A: Lead Identification and Preliminary Studies

Understanding Molecular Interactions Between Scavenger Receptor A and Its Natural Product Inhibitors Through Molecular Modeling Studies.

Design, synthesis, and characterization of rhein analogs as novel inhibitors of scavenger receptor A

Scavenger Receptor-a is a Biomarker and Effector of Rheumatoid Arthritis: A Large-Scale Multicenter Study.

Scavenger Receptor A in Immunity and Autoimmune Diseases: Compelling Evidence for Targeted Therapy

Sphingosine-1-phosphate: a Potential Therapeutic Target for Rheumatoid Arthritis

Unraveling the Therapeutic Mechanism of Saussurea involucrata against Rheumatoid Arthritis: A Network Pharmacology and Molecular Modeling-Based Investigation

SR16951, a new small molecule antagonist of MCP-1 for the treatment of autoimmune diseases (50.13)

Pattern Recognition Receptor SRA/CD204 Restricts T Cell Activation and Antitumor Immunity (52.13)

Structure activity relationship studies of natural product chemokine receptor CCR5 antagonist anibamine toward the development of novel anti prostate cancer agents.

Small Activating RNA Modulation of the G Protein‐Coupled Receptor for Cancer Treatment

A selective and potent CXCR3 antagonist SCH 546738 attenuates the development of autoimmune diseases and delays graft rejection

Molecular Recognition of CYP26A1 Binding Pockets and Structure–activity Relationship Studies for Design of Potent and Selective Retinoic Acid Metabolism Blocking Agents

SRA inhibition improves antitumor potency of antigen-targeted chaperone vaccine

SR-A Neutralizing Antibody: Potential Drug Candidate for Ameliorating Osteoclastogenesis in Rheumatoid Arthritis

Scavenger receptor a is a major homeostatic regulator that restrains drug-induced liver injury

Sinomenine Alleviates Rheumatoid Arthritis by Suppressing the PI3K-Akt Signaling Pathway, as Demonstrated Through Network Pharmacology, Molecular Docking, and Experimental Validation

Chemically Modified Small Interfering RNA Targeting Hedgehog Signaling Pathway for Rheumatoid Arthritis Therapy

Discovery of the First Selective IDO2 Inhibitor As Novel Immunotherapeutic Avenues for Rheumatoid Arthritis

Sophoridine exerts anti‐arthritic effects on fibroblast‐like synoviocytes and collagen‐induced arthritis in rats

Identification of Small-Molecule Inhibitors Against Human Leukocyte Antigen-Death Receptor 4 (HLA-DR4) Through a Comprehensive Strategy.